Gene-guided chemo for kids with relapsed solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be under 18 years old.
- The tumor has come back or hasn't responded to previous treatment.
- A special gene test (UGT1A1*6) must show the child has the normal version of the gene.
- Child must have at least one measurable tumor that can be seen on scans.
- Child should be feeling well enough to have a daily activity score of 50 or higher (out of 100).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
This trial tests a new combination of three chemotherapy drugs (irinotecan liposomes, temozolomide, and vincristine) for children and teens with solid tumors that have not responded to or have come back after standard treatment. The goal is to see if this combination can shrink or control the cancer.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or not responded to treatment. The goal is to see if this combination can shrink or control the tumor.
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
Hear when a new Pediatric Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.